Physician profile
Lisa N Rizzo
NPI 1316453616
$5,603.55
in general payments reported to CMS, 2019-2025
27 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $697 · 2022: $1,475 · 2023: $1,121 · 2024: $950 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342 · Education: $90.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.51 |
| Education | $90.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.65 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $473.27 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $431.10 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Supernus Pharmaceuticals, INC. | $366.69 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $347.64 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $300.84 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $295.41 | 2021-2023 | Trintellix |
| Alkermes, INC. | $269.58 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $255.73 | 2022-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $209.34 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $198.60 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $165.85 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $156.16 | 2023-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $123.04 | 2022-2025 | Auvelity |
| Tris Pharma INC | $109.03 | 2024-2025 | Dyanavel Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $88.56 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $84.00 | 2023-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $83.23 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $71.51 | 2024-2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $64.13 | 2021-2023 | |
| Almatica Pharma LLC | $63.90 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Collegium Pharmaceutical, INC. | $40.70 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $34.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $33.62 | 2025 | Quviviq |
| Adlon Therapeutics L.P. | $27.91 | 2021 | |
| Biogen, INC. | $23.91 | 2025 | Zurzuvae |
| Owp Pharmaceuticals, INC. | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Rizzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.